Business Wire - Monday, March 8, 1999
ANTICORT, an anticortisol, immunomodulator drug, will be evaluated in HIV positive patients under anti-HIV therapy, to determine its potential effect on various immune systems. In its initial phase, ANTICORT will be administered under different regimens, intended to ascertain its safety and eventual first indications of its clinical effectiveness.
Gregg S. Britt, Chief Executive Officer of AIDS Research Alliance, stated, "Although significant advances have been made recently in the treatment of HIV disease, currently available anti-HIV drugs have significant shortcomings. Therefore, the pursuit of more effective, better-tolerated treatments is essential. We are pleased to be working with STGI in evaluating the effects of Anticort in HIV-infected individuals."
AIDS RESEARCH Alliance is a non-profit AIDS research organization dedicated to accelerating the discovery and development of effective treatments for HIV/AIDS and a vaccine to prevent new infections.
STGI is a pharmaceutical R&D Corporation, engaged in the development of anticortisol drugs to be used in diseases/condtions associated with elevated levels of the immunosuppressive hormone cortisol. STGI's flagship anticortisol drug, ANTICORT, has been approved by the FDA to be clinically tested in an HIV population - a condition often associated with "high cortisol" that is apparently playing a major role in the destruction of the immune system as encountered in HIV+ and AIDS.
Dr. Alfred T. Sapse, President, stated, " STGI is pleased to announce the commencement of this important clinical study, and is looking forward to its results."
This release may include "forward-looking statement" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1034. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable it can give no assurance that such expectations will prove correct. This is neither an offer to buy or sell a security. For informational purposes only, from sources deemed to be reliable. For more information visit our World Wide Web page at www.anticort.com.
-30--mj/ny* csm
CONTACT: STEROIDOGENESIS Janet Greeson, Ph.D. (702) 735-7001 or PERFORMANCE STRATEGIES Richard L. Brown/Chuck Jordan (303) 471-5943 or H.L. LANZET INC. Herbert Lanzet/DeeDee Lanzet (212) 687-0061
990308
BW990303
Copyright © 1999 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .